

March 25, 2009

Encision Enters Into Sales Representation Agreement with Caldera Medical

Boulder, Colorado, March 25, 2009 -- Encision Inc. ("Encision") (OTCBB: ECIA), a medical device company owning patented surgical technology that is emerging as a standard of care in minimally-invasive surgery, has entered into an agreement with Caldera Medical, Inc. ("Caldera") to represent Caldera's line of products. Caldera's products include the Desara® Sling System for treating stress urinary incontinence which is estimated to affect 15 million women in the U.S. Encision will use its sales employees to supplement Caldera's sales team in introducing Caldera's products to physicians and hospitals.

"We are pleased to expand our product offerings to a key group of our target customers. Caldera's products are consistent with our desire to offer "best in class" products to the surgical market," said Jack Serino, President and CEO of Encision.

"Through Encision's experienced sales representatives, we will expand coverage throughout the U.S. market and strengthen our presence in the marketplace. This is especially important as we continue to broaden our product portfolio with innovative new technologies," said Bryon L. Merade, CEO of Caldera.

About Encision:

Encision designs, develops, manufactures and markets innovative surgical devices that allow surgeons to optimize technique and patient safety during a broad range of surgical procedures. Based in Boulder, Colorado, the Company pioneered the development of patented AEM® Laparoscopic Instruments to improve electrosurgery and reduce the chance for patient injury in minimally invasive surgery. For more information, visit Encision's web site at www.encision.com.

About Caldera:

Caldera is dedicated to bringing innovative medical devices to the marketplace. Caldera focuses exclusively on differentiated, high-impact products across the gynecology, urology and urogynecology specialties. Caldera is a privately held company located in Agoura Hills, California. For more information, visit Caldera's web site at www.calderamedical.com.

In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Company notes that statements in this press release and elsewhere that look forward in time, which include everything other than historical information, involve risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. Factors that could cause the Company's actual results to differ materially include, among others, its ability to increase net sales through the Company's distribution channels, insufficient quantity of new account conversions, insufficient cash to fund operations, scale up production to meet delivery obligations, delay in developing new products and receiving FDA approval for such new products and other factors discussed in the Company's filings with the Securities and Exchange Commission.

CONTACT: Marcia McHaffie, Encision Inc., 303-444-2600, mmchaffie@encision.com

Encision Inc.
Condensed Statements of Operations
(Unaudited)
(Amounts in thousands, except per share information)

Three Months Ended

Nine Months Ended

	Dec. 31, 2008	Dec. 31, 2007	Dec. 31, 2008	Dec. 31, 2007
NET SALES	\$ 3,271	\$ 3,131	\$ 9,711	\$ 8,883
COST OF SALES	1,192	1,103	3,715	3,301
GROSS PROFIT	2,079	2,028	5,996	5,582
OPERATING EXPENSES:				
Sales and marketing	1,191	1,305	3,887	3,755
General and administrative	355	331	1,080	1,053
Research and development	286	325	856	989
Total operating expenses	1,832	1,961	5,823	5,797
OPERATING INCOME (LOSS)	247	67	173	(215)
Interest and other income (expense), net	(14)	(8)	(29)	(13)
INCOME (LOSS) BEFORE PROVISION FOR INCOME TAXES	233	59	144	(228)
Provision for income taxes	—	—	—	—
NET INCOME (LOSS)	\$ 233	\$ 59	\$ 144	\$ (228)
Net income (loss) per share—basic and diluted	\$ 0.04	\$ 0.01	\$ 0.02	\$ (0.04)

Encision Inc.
Condensed Balance Sheets
(Amounts in thousands)

	Dec. 31, 2008 (unaudited)	March 31, 2008 (audited)
ASSETS		
Cash and cash equivalents	\$ 72	\$ 71
Accounts receivable, net	1,433	1,453
Inventories, net	2,098	2,271
Prepaid expenses	102	99
Total current assets	3,705	3,894
Equipment, net	811	798
Patents, net	218	199
Other assets	32	53
TOTAL ASSETS	\$ 4,766	\$ 4,944
LIABILITIES AND SHAREHOLDERS' EQUITY		
Accounts payable	\$ 673	\$ 537
Accrued compensation	293	392
Other accrued liabilities	393	481
Line of credit	199	--
Total current liabilities	1,558	1,410
Long-term debt	--	606
Common stock and additional paid-in capital	19,523	19,387

Accumulated (deficit)	(16,315)	(16,459)
Total shareholders' equity	3,208	2,928
TOTAL LIABILITIES AND SHAREHOLDERS'		
EQUITY	\$ 4,766	\$ 4,944